Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.62 EUR | -2.19% |
|
-2.38% | +14.18% |
10/06 | Almirall: extension of indication in actinic keratosis | CF |
10/06 | Almirall’s Skin Disease Drug Gets US FDA Nod for Larger Treatment Area | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.18% | 215.21Cr | |
+51.63% | 80TCr | |
+41.51% | 63TCr | |
-5.10% | 36TCr | |
+19.90% | 33TCr | |
+9.95% | 30TCr | |
+17.66% | 24TCr | |
+3.39% | 23TCr | |
+10.75% | 21TCr | |
+6.99% | 17TCr |
- Stock Market
- Equities
- ALM Stock
- News Almirall, S.A.
- Transcript : Almirall, S.A., Q1 2023 Earnings Call, May 08, 2023